| Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction |
|
SAGE Open Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Treatment of high-risk myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Treatment of lower-risk myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Treatment of lower-risk myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities |
|
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
| Treatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations |
|
Pediatric Blood & Cancer |
Aplastic Anemia |
| Treatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations |
|
Pediatric Blood Cancer |
Aplastic Anemia, Pediatric |
| Treatment of relapsed/refractory severe aplastic anemia in children: Evidence-based recommendations |
|
Pediatric Blood Cancer |
Aplastic Anemia |
| Treatment options for lower-risk myelodysplastic syndromes. Where are we now? |
|
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
| Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. |
|
Leuk Lymphoma. |
Myelodysplastic Syndromes (MDS) |
